Mikromol

Antiviral Active Pharmaceutical Ingredients (APIs) and Impurities.

QUALITY ISO 17034 | ISO/IEC 17025 ISO 9001 | GMP

lgcstandards.com/mikromol



Antiviral API and Impurity Reference Standards

Superior characterization means results that you can trust

In the developed world, it is estimated that at least 60% of infective illnesses are caused by viruses, and only 15% by bacteria. Antiviral drugs are a class of pharmaceuticals used specifically to treat viral infections. Different viruses infect different cell types through a variety of pathways, and therefore each antiviral drug is specific to a particular virus.

This catalog is a collection of antiviral API's and their respective impurities organized by API family. Each product listing is hyperlinked to the LGC Standards web shop for easy access to current pricing and availability. These products can be used for either quantitative or qualitative purposes for analytical research and development, validation studies, routine stability monitoring, or routine quality control.





It's easy to order at:



lgcstandards.com/mikromol

Technical questions? mikromol@lgcgroup.com

View your local office here

Formation of Omeprazole Sulphone by oxidative degradation of Omeprazole. (Imp. D (EP): 5-Methoxy-2-[[(4methoxy-3,5-dimethylpyridin-2-yl) methyl]sulphonyl]-IH-benzimidazole (Omeprazole Sulphone), MM0095.05)

Our quality enables your accuracy.

At Mikromol, we go beyond the standard.

Each aspect of our offering – knowledge, competency, quality, scientific intellect and transparency – is at the core of everything we do. This is how we consistently and competently deliver high-quality, globally relevant pharmaceutical reference standards that you can trust.

What 'Mikromol quality' means to us:



Producing to the highest standard.

Mikromol reference standards are produced to the highest quality, with the majority of analytical measurements performed under our ISO/IEC 17025 scope of accreditation, as well as a leading range of products manufactured according to our ISO 17034 accreditation.

We use the most advanced analytical techniques to characterise our reference standards, so that you can rely on the scientific integrity of the data contained in your Certificate of Analysis.

ŝ

Ensuring confidence from characterisation to implementation.

We use real-time stability testing and expiry date management to give you confidence in your Mikromol reference standards and ensure you receive your products as certified, ready for your analysis.

Safeguarding the integrity of your reference standards.

Our state-of-the-art global logistics and distribution centre has experienced supply chain and export departments. This ensures fast delivery of Mikromol products to our customers.



Understanding your analytical needs.

Through direct interactions with our customers and our expertise in the latest scientific and regulatory developments, we are able to quickly adapt our portfolio of reference standards to address your needs. We are committed to providing you with trusted solutions, today and tomorrow.

Providing expert support.

In LGC we combine experience with continuous training to ensure that the latest knowledge and skills are being applied to the production of Mikromol reference standards.

We are proud to connect with our customers across a global network, with dedicated local teams able to support your reference standard decisions and the implementation of our products in your analytical testing.

Our heritage, our vision, your guarantee.

Mikromol is built upon more than 25 years of history in planning, developing, producing, analysing, packaging and delivering high-quality reference standards to our customers around the world with speed and reliability. Crystallisation of Metformin Hydrochloride after removal of Methanol from the reaction mixture.

(Impurity Cyanoguanidine,

MM0056.01)


How to read your Certificate of Analysis.

Every product you receive comes with a comprehensive, multi-page Certificate of Analysis (CoA).

Each CoA provides a full description of the material to which it relates, as well as a summary of the analyses undertaken during the characterisation process.

CoA Sections

General information | Additional product information | Assay | Purity | Identity | Stability and homogeneity | Revision table



How to read your Certificate of Analysis (continued).

						_
	Mikre	പനവ	754			
8	Important Product Info	ormation				
			d is not suitable for human or anin rimary standard as described in th			
	quoted in this Certificate of Anal uncertainties and based on the I	ysis are the pr echniques des ce with the rec	scribed in this Certificate of Analys quirements of ISO 17034. The ide	e values within sis. The produc	the stated tion of this	
9	Storage and Handling					
			to warm to room temperature. No f water and other volatile material		ired, as assigned	
10	Further content					
	Assigned value					
	Identity Stability and homogeneity					
	Revision table					
	Γ					
			(Inc. Mikr	പന്ന	54	
					L	
			Assigned Value			
		1	Assay "as is": 99.43%; U = 0 The assay "as is" is assessed by		MR spectroscopy and is equival	lent to the assay based on the
			not-anhydrous and not-dried su result lies inside our acceptance	ibstance. The a	issay is verified by 100% metho	d (mass balance). The verifying
			For quantitative applications, us assay can be used for estimatio	se the assay as n/calculation o	a calculation value on the "as is f measurement uncertainty.	s basis". The uncertainty of the
			Method 1: Value assigning	technique - q	uantitative NMR spectroscop	у
			Conditions Internal Standard		400 MHz, CDCl ₃	nzono (contified reference
	LGC GmbH, Louis-Pasteur-Str. 30, MM0007.00-0250				2,3,5,6-Tetrachloro-1-nitrobe material), signal 7.6 – 8.00 p	ppm, 1H
			Results (mass fraction, n=6) Quantitative NMR spectrum		99.43%; U=0.57%	
			Quantitative NMK spectrum			
				1		11
				lr	ı	L
			10 10 00 00 00 00 0	·	· · · · · · · · · · · · · · · · · · ·	
			Method 2: Value verifying t	echnique - 10	00% method	
			100% method (mass balan	ce) with		
			chromatographic purity by Result	nPLC	99.86%	
		12	The calculation of the 100% me	thod follows th	ne formula:	
			Assay (%) = (100% - volatile c		B 11 (01)	
			Volatile contents are considered Inorganic residues are excluded	l as absolute co l by additional	ontributions and purity is consid tests.	ered as relative contribution.
			LGC GmbH, Louis-Pasteur-Str. 30, I	D-14943 Luckenv		Page
			MM0007.00-0250		Lot number G1010777	

Additional product

information 8 Confirmation of primary standard status for standards manufactured according to ISO 17025 and

ISO 17034 Storage and handling recommendations

0 Content of the CoA (varies depending on the product quality level)

Assay Section

- 1 Assay result and details about assay assigning technique. For ISO 17034 products and products manufactured according to ISO 17025 this will be an ISO 17025-accredited absolute method. For ISO 9001 products the assay will usually be assigned by mass balance calculated from the values given in the purity section
- 12 Details about the verifying assay for ISO 17034 products and products manufactured according to ISO 17025. This assay confirms the result of the absolute method and is assessed by a second, independent method, usually mass balance calculated from the values given in the purity section

Page 3/8

How to read your Certificate of Analysis (continued).

Area Percent R				
40°C DAD, 210nm Auto 5µ; 0.1631mg/ml in Wate 1.0ml/mln, Water, 0.1% H ₂ PO ₄ Accontrictile, 0.1% H ₂ PO ₄ 0-9min A/B 85/15 0-2min A/B to 55/15 14-24min A/B to 55/15 14-24min A/B 85/15 (v/v) a 3 - Subwitne - 7.343 Area Percent R	er/Acetonitrile 50/50 (v/v			
Auto Sµl; 0.1631mg/ml in Wat 1.0ml/min, Water, 0.1% H_PO_ Acetonitrile, 0.1% H_PO_ 0-9min A/B 85/15 9-12min A/B 85/15 12-24min A/B 85/15 (v/v) a 3-5ubstere - 7,243 Area Percent R				
1.0ml/min, Water, 0.1% H ₁ PO ₄ Acetonitrile, 0.1% H ₁ PO ₄ 0-9min A/B 85/15 9-12min A/B to 50/50 12-24min A/B 85/15 (v/v) 9- 3- Substance - 7,243 Area Percent R				
Acetonitrile, 0.1% H PO, 0-9min A/B 85/15 9-12min A/B to 50/50 12-14min A/B to 85/15 14-24min A/B 85/15 (v/v) 9 3-8dekterer.7343 Area Percent R	Mikromo			
0-9min A/B 85/15 9-12min A/B to 55/50 12-14min A/B to 55/51 14-24min A/B 85/15 (v/v) 14-24min A/B 85/15 (v/v) 14-34min A/B 85/15 (v/v) 14-24min A/	Mikromo			
9-12min A/B to 50/50 12-14min A/B to 50/15 14-24min A/B 85/15 (v/v) a 3-5ubstere - 7,243	Mikrom			
3 - Substance - 7,243	Mikrom	ol		
1 3.330	eport - Sorted by Sign ition time Area 0.056	al Ar	rea% 04	
2 5.817	0.050		04	
3 7.243 Totals	127.5	······	0.92 00.00	
				d the cumulative
Result (n=6)				
14 Volatile content				
Loss on drying				
			8.7 (2.2.32)	
Result (II=3)	0.07 %	, 3D = 0.01 %		
Inorganic residu	ies			
Method: Sulpha	ted ash, EP 8.7, chapter	2.4.14*		
those detectable b	y sulphated ash is highly	y unlikely. Inorganic re	sidues can be exclud	ed by results of
sulphated ash. Th		ion was performed for	inorganic impurities.	
not accredited te	acing method			
	the purities, added Result (n=6) Volatile content Loss on drying Method Result (n=3) Inorganic residu Method: Sulpha According to the a sulphated ash. Th	the purties, added up to 100 %. System p Result (n=6) 99.9: Volatile content Loss on drying Method 105 °C Result (n=3) 0.07 % Inorganic residues Method: Sulphated ash, EP 8.7, chapter those detectable by sulphated ash is highlit	Id Volatile content Loss on drying Method 105 *C to constant mass, EP: Result (n=3) 0.07 %; SD = 0.01 %* Inorganic residues Method: Suphated ash, EP 8.7, chapter 2.4.14* According to the available data, the presence of inorganic impurit Hethod: Suphated ash, EP 8.7, chapter 2.4.14*	Volatile content Loss on drying Method 105 °C to constant mass, EP 8.7 (2.2.32) Result (n=3) 0.07 %; SD = 0.01 %* Inorganic residues Method: Sulphated ash, EP 8.7, chapter 2.4.14* According to the available data, the presence of inorganic impurities in the reference the detectable by sulphated ash. Itophy unlikely, inorganic residues can be exclude sulphated ash. Therefore, no assay correction was performed for inorganic impurities

Purity section

- Organic purity is usually assessed by HPLC or GC. Conditions, chromatogram and area report are displayed
- Volatile content: Water content is determined by Karl Fischer titration.
 Residual solvents are estimated by the use of 'H-NMR or determined by GC/headspace techniques.
 Alternatively the combined volatile content is determined by LOD
- Inorganic residues are excluded by either the results of elementary analysis or by sulphated ash for ISO 17034 products and products manufactured according to ISO 17025



Product Code

Product

Product Code	Product	CAS No.	CS Unit	
bacavir Su	Ifate			
<u>MM3249.00</u>	Abacavir Sulfate	188062-50-2	250mg	
<u>MM3249.01</u>	 Impurity C (EP): [(1S,4R)-4-(2,6-Diamino-9H-purin-9-yl) cyclopent-2-enyl]methanol Related compound A (USP): [4-(2,6-diamino-9H-purin-9-yl) cyclopent-2-enyl]methanol 	124752-25-6	100mg	H ₂ N NH ₂ N NN NN NN NN NN NN NN NN NN NN NN NN N
<u>MM3249.02-</u> 0025	 [(1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl] methanol Hydrochloride Related compound C (USP): [(1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl]methanol 	172015-79-1	25mg	N H ₂ N N N N N N N N N N N N N N N N N N N
ciclovir (Ac	cyclovir)			
<u>MM0061.00</u>	♦ Aciclovir	59277-89-3	500mg	
<u>MM0061.01</u>	Impurity A (EP): 2-[(2-Amino-6-oxo-1,6- dihydro-9H-purin-9-yl)methoxy]ethyl Acetate Related compound A (USP): 2-[(2-amino-6-oxo-1,6-dihydro- 9H-purin-9-yl)methoxy]ethyl acetate	102728-64-3	100mg	
<u>MM0061.02</u>	Impurity B (EP): 2-Amino-1,7-dihydro-6H- purin-6-one (Guanine)	73-40-5	100mg	HN H ₂ N N
<u>MM0061.03</u>	Impurity C (EP): 2-Amino-7-[(2-hydroxy- ethoxy)methyl]-1,7-dihydro-6H-purin- 6-one	91702-61-3	100mg	
<u>MM0061.04</u>	 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin- 9-yl)methoxy]ethyl Benzoate 	59277-91-7	100mg	
<u>MM0061.06</u>	 Impurity F (EP): N-[9-[(2-Hydroxyethoxy)-methyl]-6-oxo-6,9-dihydro-1H-purin-2- ♦ yl]acetamide Related compound F (USP): N-[9-[(2-Hydroxyethoxy) methyl]-6-oxo-6,9-dihydro-1H-purin-2-yl]acetamide 	110104-37-5	100mg	
<u>MM0061.07</u>	 Impurity G (EP): 2-[[(2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-9-yl]- ♦ methoxy]ethyl Acetate Related compound G (USP): 2-[2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-9-yl]methoxyethyl acetate 	75128-73-3	100mg	L _n L,
<u>MM0061.08</u>	2-[[2-(Acetylamino)-6-oxo-1,6-dihydro- 9H-purin-9-yl]methoxy]ethyl Benzoate	133186-23-9	100mg	
<u>MM0061.10</u>	2,6-Dichloropurine	5451-40-1	100mg	
<u>MM0061.12</u>	♦ N ² -Acetylguanine	19962-37-9	100mg	

Adefovir Dipivoxil

<u>MM3505.00</u>	 Adefovir Dipivoxil 	
------------------	--	--


142340-99-6



250mg

Product Code	Product	CAS No.	CS	Unit	
Amprenavir					
<u>MM3582.00</u>	♦ Amprenavir	161814-49-9		100mg	
Atazanavir S	Sulfate				
<u>MM3514.00</u>	♦ Atazanavir Sulfate	229975-97-7		100mg	with x
<u>MM3514.02</u>	 Impurity J (EP): <i>tert</i>-Butyl 2-[(2<i>S</i>,3<i>S</i>)-3-(<i>tert</i>-Butoxyformamido)-2-hydroxy-4-phenylbutyl]-2-[[4-(pyridin-2- yl)phenyl]methyl]hydrazine-1-carboxylate (<i>tert</i>-Butyl <i>N</i>-[(1<i>S</i>,2<i>S</i>)-1-Benzyl-3-[(tert-butoxycarbonylamino)-[[4-(2-pyridyl)phenyl]methyl]amino]-2-hydroxy-propyl]carbamate) 	198904-86-8		100mg	
<u>MM3514.03-</u> 0025	 Impurity K (EP): (2<i>S</i>)-2-(Methoxyformamido)-3,3-dimethylbutanoic Acid ((<i>S</i>)-2-(Methoxycarbonylamino)-3,3- dimethylbutanoic Acid) Related compound A (USP): (S)-2-[(Methoxycarbonyl) amino]-3,3-dimethylbutanoic acid 	162537-11-3		25mg	N H OH
Cidofovir					
<u>MM3558.00</u>	♦ Cidofovir	113852-37-2		100mg	NH2 OV POH OH
Darunavir Et	thanolate				
<u>MM3624.00-</u> 0250	Darunavir Ethanolate	635728-49-3		250mg	
<u>MM3624.02-</u> <u>0025</u>	 [(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl] (2,5- Dioxopyrrolidin-1-yl) Carbonate 	253265-97-3		25mg	
<u>MM3624.04-</u> <u>0025</u>	tert-Butyl N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[(2-methylpropyl) [(4-nitrophenyl)sulfonyl]amino]propyl]carbamate	191226-98-9		25mg	$X_{\mathcal{O}} \overset{\text{l}}{\underset{H}{\overset{OH}{\longrightarrow}}} \overset{\text{O}}{\underset{H}{\overset{OH}{\longrightarrow}}} \overset{\text{O}}{\underset{OH}{\overset{OH}{\longrightarrow}}} \overset{\text{O}}{\underset{OH}{\longrightarrow}} \overset{\text{O}}{\underset{OH}{\longrightarrow}} \overset{\text{O}}{\underset{OH}{\overset{OH}{\longrightarrow}}} \overset{\text{O}}{\underset{OH}{\overset{OH}{\overset}}} \overset{\text{O}}{\underset{OH}{\overset{OH}{\overset}}} \overset{O}{\underset{OH}{\overset{OH}{\overset{OH}{\longrightarrow}}} \overset{O}{\underset{OH}{\overset{OH}{\overset}}} \overset{O}{\underset{OH}{\overset{OH}{\overset{OH}{\overset}}} \overset{O}{\underset{OH}{\overset{OH}{\overset}}} \overset{O}{\underset{OH}{\overset{OH}{\overset}}} \overset{O}{\underset{OH}{\overset}} \overset{O}{\overset{OH}{\overset}} \overset{O}{\underset{OH}{\overset{OH}{\overset}}} \overset{O}{\overset{OH}{\overset}} \overset{O}{\underset{OH}{\overset}} \overset{O}{\overset}} \overset{O}{\underset{OH}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset} \overset{O}{\overset}} \overset{O}{\overset}} \overset{O}{\overset$
<u>MM3624.07-</u> 0025	tert-Butyl N-[(1S)-1-((2S)-Oxiran-2-yl)-2-phenylethyl] carbamate	98737-29-2		25mg	
<u>MM1560.00</u>	‡ Phenylalanine (L-Phenylalanine)	63-91-2		250mg	NH ₂ OH
Didanosine					
<u>MM1047.00</u>	♦ Didanosine	69655-05-6		250mg	

Product Code	Product	CAS No.	CS	Unit	
<u>MM1047.01</u>	 Impurity A (EP): 1,7-Dihydro-6H-purin-6-one (Hypoxanthine) Related compound A (USP): Hypoxanthine 	68-94-0		100mg	HN N N H
<u>MM1047.02</u>	Impurity G (EP): 9-(2,3-Dideoxy-β-D-glycero- pentofuranosyl)-9H-purin-6-amine (2',3'-Dideoxyadenosine) Related compound B (USP): 2',3'-dideoxyadenosine	4097-22-7		100mg	HO NO NO
Efavirenz					
<u>MM0919.00</u>	♦ Efavirenz	154598-52-4		250mg	
<u>MM0919.03</u>	 (S)-2-(2-Amino-5-chlorophenyl)-4-cyclopropyl-1,1,1- trifluorobut-3-yn-2-ol Related compound A (USP): (S)-2-(2-amino-5-chlorophenyl)- 4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol 	209414-27-7		100mg	CI F-CI OH
<u>MM0919.05</u>	 6-Chloro-2-cyclopropyl-4-(trifluoromethyl)quinoline Related compound C (USP): 6-chloro-2-cyclopropyl-4- (trifluoromethyl)quinoline 	391860-73-4		100mg	
<u>MM0919.06-</u> <u>0025</u>	♦ Efavirenz Racemic	177530-93-7		25mg	
<u>MM0919.07</u>	◆ N-(4-Methoxybenzyl)-4-chloro-2-(trifluoroacetyl)aniline	173676-54-5		100mg	
Elvitegravir					
<u>MM3372.00</u>	♦ Elvitegravir	697761-98-1		100mg	
Emtricitabine	e				
<u>MM1325.00</u>	♦ Emtricitabine	143491-57-0		100mg	NH ₂ N F O N HO
<u>MM1325.01</u>	 Emtricitabine L-Menthyl Ester ((2R,5S)-5-(4-Amino-5-fluoro-2- oxo-1(2H)-pyrimidinyl)-1,3-oxathiolane-2-carboxylic Acid (1R,2S,5R)-5-Methyl-2-(1-methylethyl)cyclohexyl Ester) 	764659-72-5		100mg	



Product Code	Product	CAS No.	CS	Unit	
<u>MM0355.00</u>	◆ Flucytosine	2022-85-7		250mg	NH ₂ NH ₂ F
Entecavir Mo	onohydrate				
<u>MM3314.00</u>	♦ Entecavir Monohydrate	209216-23-9		250mg	H ₂ N N N H ₀ O
<u>MM3314.01</u>	◆ Entecavir N ² -Isomer	n/a		5mg	HN N H HN N H HO HO
<u>MM3314.02-</u> 0025	♦ 3',5'-Di-O-Benzylentecavir	142217-81-0		25mg	
Famciclovir					
<u>MM0620.00</u>	♦ Famciclovir	104227-87-4		250mg	$= \sum_{k=N}^{N} \sum_{i=1}^{N} \sum_{j=1}^{N} \sum_{i=1}^{N} \sum_$
<u>MM0620.01</u>	 9-[4-Acetoxy-3-(acetoxymethyl)butyl]-2-amino- 6-chloropurine 	97845-60-8		100mg	H ₂ N L _N C _O
<u>MM0620.02</u>	2-[2-(2-Amino-9H-purin-9-yl)ethyl]propane-1,3-diol Hydrochloride Related compound A (USP): 2-[2-(2-Amino-9H-purin-9-yl) ethyl]propane-1,3-diol	246021-75-0		100mg	HAN N N OH HCI
<u>MM0620.20-</u> 0025	 2-Amino-6-chloropurine Related compound F (USP): 2-Amino-6-chloropurine 	10310-21-1		25mg	$H_{2N} \bigvee_{N} \bigvee_{N} H_{H_{2N}} \bigvee_{N} H_$
Foscarnet S	odium Hexahydrate				
<u>MM3500.01</u>	Impurity B (EP) as Disodium Salt: Disodium (Ethoxyoxydophosphanyl)formate Related compound B (USP): (Ethoxyoxidophosphanyl) formic acid	55920-24-6		50mg	$ \begin{array}{c} \overbrace{\begin{subarray}{c} 0 \\ 0 \\ 0 \end{array}}^{\begin{subarray}{c} 0 \\ 0 \end{array}} \left[\begin{array}{c} Na^{*} \end{array} \right]_{2} \end{array} $
<u>MM3500.02</u>	Impurity D (EP): Ethyl (Diethoxyphosphoryl)formate Related compound D (USP): O,O-diethyl ethoxycarbonylphosphonate	1474-78-8		100mg	
Ganciclovir					
<u>MM0485.00</u>	Ganciclovir	82410-32-0		100mg	
<u>MM0061.02</u>	 Impurity F (EP): 2-Amino-1,9-dihydro-6<i>H</i>-purin- 6-one (Guanine) 	73-40-5		100mg	$H_{2N} \xrightarrow{O} H_{N} \xrightarrow{H} N$

Product Code	Product	CAS No. CS	Unit	
<u>MM0485.08</u>	Impurity H (EP): 2-Amino-7-[[2-hydroxy-1-(hydroxy- methyl)ethoxy]methyl]-1,7-dihydro-6 <i>H</i> -purin-6- one (N-7 Isomer of Ganciclovir)	84222-50-4	50mg	HO H ₂ N N N N N
<u>MM0485.09</u>	 Impurity I (EP): 2-[(2-Amino-6-oxo-1,6-dihydro- 9H-purin-9-yl)methoxy]-propane-1,3-diyl Dipropanoate (Ganciclovir Dipropionate) 	86357-20-2	100mg	HAN N N N N N N N N N N N N N N N N N N
<u>MM0485.10</u>	Impurity J (EP): 2-[2-(Propanoylamino)-6-oxo-1,6- dihydro-9H-purin-9-yl]methoxy]propane-1,3- diyl dipropanoate (Ganciclovir Tripropionate)	177216-32-9	100mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
<u>MM0485.12</u>	Ganciclovir Mono-O-acetate	88110-89-8	100mg	
<u>MM0485.14-</u> 0025	♦ Ganciclovir Triacetate	86357-14-4	25mg	L'''L''
Idoxuridine				
<u>MM0791.00</u>	♦ Idoxuridine	54-42-2	500mg	
Lamivudine				
<u>MM0749.00-</u> 0250	‡ Lamivudine	134678-17-4	250mg	
<u>MM0045.00-</u> 0250	‡ Impurity C (EP): Salicylic Acid	69-72-7	250mg	ОН
<u>MM0749.05-</u> 0025	 Impurity E (EP): 4-Aminopyrimidin-2(1H)-one (Cytosine) 	71-30-7	25mg	NH ₂ NH ₂ NH ₂ H
<u>MM0593.03-</u> 0025	 Impurity F (EP): Pyrimidine-2,4(1H,3H)-dione (Uracil) 	66-22-8	25mg	HN O H
Moroxydine	Hydrochloride			
<u>MM1749.00</u>	Moroxydine Hydrochloride	3160-91-6	250mg	

Product Code

Product

Nevirapine MM1146.00-± Nevirapine Anhydrous 129618-40-2 250mg 0250 Impurity A (EP): 11-Ethyl-4-methyl-5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e][1,4]diazepin-6-one MM1146.01 133627-17-5 100mg Related compound A (USP): 5,11-dihydro-6H-11-ethyl-4methyl-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one Impurity B (EP): 4-Methyl-5,11-dihydro-6Hdipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one MM1146.02 287980-84-1 100mg Related compound B (USP): 5,11-Dihydro-4-methyl-6Hdipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one Impurity C (EP): 4-Methyl-11-propyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one MM1146.03 ٠ 287980-85-2 100mg Related compound C (USP): 5,11-Dihydro-6H-11-propyl-4methyl-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one MM1146.04 3-Amino-2-chloro-4-methylpyridine 133627-45-9 100mg 2-Chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-MM1146.05 133627-46-0 100mg pyridinecarboxamide 1027324-99-7 MM1146.06 Nevirapine N10-Oxide 50mg MM1146.07 Nevirapine N1-Oxide 162255-73-4 100mg

Oseltamivir Phosphate

<u>MM1239.00</u>	the set of the se	204255-11-8 250m	$g \xrightarrow{{}^{\mu_{H}}}_{{}^{\mu_{H}}} \xrightarrow{{}^{\mu_{H}}}_{{}^{\mu_{H}}} \xrightarrow{{}^{\mu_{H}}}_{{}^{\mu_{H}}} \xrightarrow{{}^{\mu_{H}}}_{{}^{\mu_{H}}}$			
<u>MM1239.03</u>	Impurity H (EP): Tributylphosphane Oxide	814-29-9 100m				
Pleconaril						
<u>MM3562.00</u>	♦ Pleconaril	153168-05-9 100m				
Raltegravir Potassium						
<u>MM3375.00</u>	♦ Raltegravir Potassium	871038-72-1 100m	$-\sum_{k=1}^{\infty}\sum_{j=1}^{k}\sum_{k=1}^{\infty}\sum_{k=1}^{j}\sum_{k=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{k=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{k=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{j=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^{\infty}\sum_{j=1}^{\infty}\sum_{j=1}^{\infty}\sum_{i=1}^$			

Product Code	Product	CAS No. C	S Unit	
Ribavirin				
<u>MM0542.00</u>	♦ Ribavirin	36791-04-5	250mg	H ₂ N N N O O O H
<u>MM0542.01</u>	 Impurity A (EP): 1-β-D-Ribofuranosyl-1H-1,2,4- triazole-3-carboxylic Acid Related compound A (USP): 1-beta-D-ribofuranosyl-1H- 1,2,4-triazole-3-carboxylic acid 	39925-19-4	100mg	но Л но
<u>MM0542.03</u>	Impurity C (EP): 1H-1,2,4-Triazole-3-carboxylic Acid	4928-87-4	100mg	HO N N N H
<u>MM0542.04</u>	Impurity D (EP): 1H-1,2,4-Triazole-3-carboxamide Related compound D (USP): 1H-1,2,4-triazole-3- carboxamide	3641-08-5	100mg	
<u>MM0542.05</u>	 1-(5-O-Benzoyl-β-D-ribofuranosyl)-1H-1,2,4- triazole-3-carboxamide (5'-O-Benzoylribavirin) 	58151-90-9	100mg	
<u>MM0542.06</u>	Impurity F (EP): 1-(5-O-AcetyI-β-D- ◆ ribofuranosyI)-1H-1,2,4-triazole-3- carboxamide (5'-O-AcetyIribavirin)	58151-87-4	100mg	
Rilpivirine H	ydrochloride			
<u>MM3376.00</u>	Rilpivirine Hydrochloride	700361-47-3	100mg	M ANGERO
<u>MM3376.02-</u> <u>0025</u>	 ↓ 4-[[4-[(4-Bromo-2,6-dimethylphenyl)amino]-2-pyrimidinyl] ↓ amino]benzonitrile 	374067-85-3	25mg	
<u>MM3376.06-</u> 0025	♦ 4-Aminobenzonitrile	873-74-5	25mg	NH2
Rimantadine	e Hydrochloride			
<u>MM0913.00</u>	Rimantadine Hydrochloride	1501-84-4	250mg	HCI

Product Code	Product	CAS No.	CS Unit	
Ritonavir				
<u>MM1034.00</u>	♦ Ritonavir	155213-67-5	100mg	the the the
<u>MM1034.01-</u> 0025	 Impurity A (EP): (2S)-3-Methyl-2-[[methyl[[2-(1-methylethyl) thiazol-4-yl]methyl]carbamoyl]amino]butanoic Acid 	154212-61-0	25mg	S-1 V OH V N N OH
<u>MM1034.23</u>	4-Nitrophenyl Thiazol-5-ylmethyl Carbonate	144163-97-3	100mg	or ^N Co Co
<u>MM1034.26</u>	 ◆ 2-Methylpropanethioamide 	13515-65-6	100mg	NH ₂
<u>MM0045.11</u>	◆ Phenol	108-95-2	100mg	ОН
<u>MM0042.03</u>	♦ 4-Nitrophenol	100-02-7	100mg	0 НО N 0 ⁻
Saquinavir N	<i>l</i> esilate			
<u>MM0402.00</u>	Saquinavir Mesilate	149845-06-7	250mg	
Stavudine				
<u>MM0534.00</u>	♦ Stavudine	3056-17-5	100mg	HN HN HO
<u>MM0534.01</u>	Impurity A (EP): 5-Methylpyrimidine-2,4(1H,3H)- dione (Thymine)	65-71-4	100mg	
<u>MM0534.03</u>	Impurity C (EP): 1-(2-Deoxy-β-D-erythro-pento- furanosyl)-5-methylpyrimidine-2,4(1H,3H)-dione (Thymidine)	50-89-5	100mg	HN O HO O O HO O O H
<u>MM0534.04</u>	Impurity I (EP): 1-(5-O-Benzoyl-2,3-dideoxy-β-D-glycero- pent-2-enofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione	122567-97-9	100mg	

Product Code	Product	CAS No.	CS Unit	
Telaprevir				
<u>MM3379.02</u>	(1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-Cyclohexyl-2-[(2- pyrazinylcarbonyl)amino]acetyl]amino]-3,3-dimethyl-1- oxobutyl]octahydrocyclopenta[c]pyrrole-1-carboxamide	1616728-72-3	100mg	
Tenofovir Di	soproxil Fumarate			
<u>MM1329.00</u>	Tenofovir Disoproxil Fumarate	202138-50-9	100mg	the state of the s
<u>MM1329.02</u>	 ♦ (R)-9-(2-Hydroxypropyl)adenine (Desphosphoryltenofovir) 	14047-28-0	100mg	NH2 NNNNNNOH
<u>MM1495.00</u>	♦ Adenine	73-24-5	250mg	NH2 N N N N
Valaciclovir	Hydrochloride, Anhydrous (Valacyclovir Hydroch	nloride)		
<u>MM0061.02</u>	Impurity A (EP): 2-Amino-1,9-dihydro-6H- purin-6-one (Guanine)	73-40-5	100mg	HN H ₂ N N N
<u>MM0061.00</u>	Impurity B (EP): 2-Amino-9-[(2-hydroxy- ◆ ethoxy)methyl]-1,9-dihydro-6 <i>H</i> -purin-6- one (Aciclovir)	59277-89-3	500mg	
<u>MM0619.05</u>	Impurity E (EP): 2-[(2-Amino-6-oxo-1,6-dihydro-9 <i>H</i> -purin-9- yl)methoxy]ethyl <i>N</i> -[(Benzyloxy)carbonyl]-L-valinate Related compound E (USP): 2-[(2-amino-6-oxo-1,6-dihydro- 9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)carbonyl]-L- valinate	124832-31-1	100mg	
<u>MM0619.19-</u> 0025	Impurity F (EP) as para-Toluenesulfonate: 2-Hydroxyethyl L- Valinate para-Toluenesulfonate Related compound F (USP): 2-hydroxyethyl valinate	86150-61-0	25mg	HO~OF HO
<u>MM0619.07</u>	 Impurity G (EP): N,N-Dimethylpyridin-4-amine Related compound G (USP): N,N-dimethylpyridin-4-amine 	1122-58-3	100mg	N N
<u>MM0061.01</u>	Impurity I (EP): 2-[(2-Amino-6-oxo-1,6-dihydro- 9 <i>H</i> -purin-9-yl)methoxy]ethyl Acetate	102728-64-3	100mg	
Valaciclovir	Hydrochloride, Hydrated			
<u>MM3012.00</u>	Valaciclovir Hydrochloride Monohydrate	521915-75-3	250mg	
Valganciclov	/ir Hydrochloride			
<u>MM3267.00-</u> 0250	♦ Valganciclovir Hydrochloride	175865-59-5	250mg	NA CONTRACTOR

Product Code	Product	CAS No.	CS Unit	
<u>MM3267.02-</u> <u>0025</u>	 ♦ 9-Methoxymethylguanine 	1202645-50-8	25mg	H ₂ N N N O
<u>MM0485.12</u>	Ganciclovir Mono-O-acetate	88110-89-8	100mg	
Vidarabine Monohydrate				
<u>MM3639.00</u>	Vidarabine Monohydrate	24356-66-9	250mg	NH2 N H2 H0 OH H2O
Zidovudine				
<u>MM0534.00</u>	Impurity A (EP): 1-[(2R,5S)-5-(Hydroxymethyl)- ◆ 2,5-dihydrofuran-2-yl)-5-methylpyrimidine- 2,4(1H,3H)-dione (Stavudine)	3056-17-5	100mg	HN O HO HO
<u>MM0173.02</u>	Impurity B (EP): 1-(3-Chloro-2,3-dideoxy-β-D- erythro-pentofuranosyl)-5-methylpyrimidine- 2,4(1H,3H)-dione Related compound B (USP): 3'-chloro-3'-deoxythymidine	25526-94-7	100mg	HN HO CI
<u>MM0534.01</u>	Impurity C (EP): 5-Methylpyrimidine-2,4(1H,3H)- ♦ dione (Thymine) Related compound C (USP): thymine	65-71-4	100mg	HN O H
<u>MM0173.04</u>	Impurity D (EP): Triphenylmethanol	76-84-6	100mg	С
<u>MM0534.03</u>	Impurity E (EP): 1-(2-Deoxy-β-D-erythro-pentofuranosyl)-5- methylpyrimidine-2,4(1H,3H)-dione (Thymidine) Related compound D (USP): [1-(2-Deoxy-beta-D- ribofuranosyl)]thymine	50-89-5	100mg	

Mikromol worldwide

1 Brazil

- +55 12 3302 5880 Т
- Е bz@lgcstandards.com

Bulgaria 2

- Т +359 (0)2 971 4955 Е
- bg@lgcstandards.com

China 3

- +86 400 9216156 Т
- info.china@lgcgroup.com Е

4 France

- +33 (0)3 88 04 82 82 Т
- Е fr@lgcstandards.com

5 Germany

- +49 (0)281 9887 0 Т
- de@lgcstandards.com Е

6 Hungary

- Т +40 364 116890 Е
- ro@lgcstandards.com
- 7 India +919082974025 Т
- Е india@lgcgroup.com

8 Ireland

- +44 (0)20 8943 8480 Т
- Е uksales@lgcstandards.com

9 Italy

Е

Е

- +39 02 22476412 Т
- it@lgcstandards.com Е

10 Middle East

- +49 (0) 281 9887 0 т
 - fr@lgcstandards.com

11 Netherlands

+49 (0)281 9887 250 т

E nl@lgcstandards.com

12 Nordic Countries +49 (0)281 9887 0 Т

- de@lgcstandards.com

13 Poland

- Т +48 22 751 31 40
- E pl@lgcstandards.com

14 Romania

- T +40 364 116890
- E ro@lgcstandards.com

15 Russia +7 812 777 04 88 Т

E ru@lgcgroup.com

16 South Africa

- +27 (0)11 466 4321 Т
- sales.za@lgcgroup.com Е

17 Spain

- +34 (0)93 308 4181 т
- es@lgcstandards.com Е

18 UK reference materials

+44 (0)20 8943 8480 т E uksales@lgcstandards.com

19 USA + Canada

- +1 (603) 622 7660 Т
- lgcusa@lgcgroup.com Е

Export queries

- T +49 (0) 281 9887 250
- E global.sales@lgcgroup.com

LGC does not guarantee availability and reserves the right to discontinue any product. LGC does not accept liability for any loss that is caused by inaccurate customer selection, product information or inappropriate use of a product. Unless otherwise stated all trademarks are the property of LGC or its affiliated group companies. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any retrieval system, without the written permission of the copyright holder.

Copyright © LGC Limited 2020. All rights reserved. Mikromol is a trademark owned by LGC GmbH.

Mikromol

Acetylation of 2,6-Dimethylaniline during the synthesis of Lidocaine. (Impurity N-(2,6-Dimethylphenyl) acetamide, MM0102.08)

Copyright © LGC Limited 2020. All rights reserved.